Logo image of RCKT

ROCKET PHARMACEUTICALS INC (RCKT) Stock Fundamental Analysis

USA - NASDAQ:RCKT - US77313F1066 - Common Stock

2.84 USD
-0.04 (-1.39%)
Last: 11/20/2025, 8:21:04 PM
2.87 USD
+0.03 (+1.06%)
After Hours: 11/20/2025, 8:21:04 PM
Fundamental Rating

2

Overall RCKT gets a fundamental rating of 2 out of 10. We evaluated RCKT against 533 industry peers in the Biotechnology industry. Both the profitability and financial health of RCKT have multiple concerns. RCKT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RCKT has reported negative net income.
RCKT had a negative operating cash flow in the past year.
RCKT had negative earnings in each of the past 5 years.
In the past 5 years RCKT always reported negative operating cash flow.
RCKT Yearly Net Income VS EBIT VS OCF VS FCFRCKT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

RCKT has a Return On Assets (-61.19%) which is in line with its industry peers.
The Return On Equity of RCKT (-72.72%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -61.19%
ROE -72.72%
ROIC N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
RCKT Yearly ROA, ROE, ROICRCKT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCKT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCKT Yearly Profit, Operating, Gross MarginsRCKT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for RCKT has been increased compared to 1 year ago.
Compared to 5 years ago, RCKT has more shares outstanding
Compared to 1 year ago, RCKT has a worse debt to assets ratio.
RCKT Yearly Shares OutstandingRCKT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
RCKT Yearly Total Debt VS Total AssetsRCKT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -3.13, we must say that RCKT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.13, RCKT is in line with its industry, outperforming 48.41% of the companies in the same industry.
RCKT has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.05, RCKT is not doing good in the industry: 60.60% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z -3.13
ROIC/WACCN/A
WACCN/A
RCKT Yearly LT Debt VS Equity VS FCFRCKT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 6.39 indicates that RCKT has no problem at all paying its short term obligations.
RCKT has a better Current ratio (6.39) than 66.42% of its industry peers.
A Quick Ratio of 6.39 indicates that RCKT has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.39, RCKT is doing good in the industry, outperforming 67.17% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.39
Quick Ratio 6.39
RCKT Yearly Current Assets VS Current LiabilitesRCKT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 19.27% over the past year.
EPS 1Y (TTM)19.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.62%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RCKT will show a quite strong growth in Earnings Per Share. The EPS will grow by 11.89% on average per year.
RCKT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 473.92% yearly.
EPS Next Y20.79%
EPS Next 2Y18.74%
EPS Next 3Y13.63%
EPS Next 5Y11.89%
Revenue Next Year1817.18%
Revenue Next 2Y2556.94%
Revenue Next 3Y964.73%
Revenue Next 5Y473.92%

3.3 Evolution

RCKT Yearly Revenue VS EstimatesRCKT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
RCKT Yearly EPS VS EstimatesRCKT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RCKT. In the last year negative earnings were reported.
Also next year RCKT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCKT Price Earnings VS Forward Price EarningsRCKT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCKT Per share dataRCKT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A more expensive valuation may be justified as RCKT's earnings are expected to grow with 13.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.74%
EPS Next 3Y13.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCKT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ROCKET PHARMACEUTICALS INC

NASDAQ:RCKT (11/20/2025, 8:21:04 PM)

After market: 2.87 +0.03 (+1.06%)

2.84

-0.04 (-1.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-25 2026-02-25/amc
Inst Owners88.61%
Inst Owner Change0.71%
Ins Owners2.97%
Ins Owner Change29.16%
Market Cap306.44M
Revenue(TTM)N/A
Net Income(TTM)-257.58M
Analysts75.45
Price Target7.95 (179.93%)
Short Float %10.63%
Short Ratio4.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.33%
Min EPS beat(2)-3.91%
Max EPS beat(2)10.56%
EPS beat(4)3
Avg EPS beat(4)7.6%
Min EPS beat(4)-3.91%
Max EPS beat(4)15.34%
EPS beat(8)6
Avg EPS beat(8)7.93%
EPS beat(12)7
Avg EPS beat(12)4.77%
EPS beat(16)9
Avg EPS beat(16)1.82%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.58%
PT rev (3m)-7.95%
EPS NQ rev (1m)-0.38%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.02%
EPS NY rev (3m)4.45%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-14.89%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-95.4%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-2.22
EYN/A
EPS(NY)-1.61
Fwd EYN/A
FCF(TTM)-1.91
FCFYN/A
OCF(TTM)-1.89
OCFYN/A
SpS0
BVpS3.28
TBVpS2.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.19%
ROE -72.72%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.2%
ROA(5y)-38.05%
ROE(3y)-50.34%
ROE(5y)-43.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.36%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.39
Quick Ratio 6.39
Altman-Z -3.13
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)144.02%
Cap/Depr(5y)620.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.27%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.62%
EPS Next Y20.79%
EPS Next 2Y18.74%
EPS Next 3Y13.63%
EPS Next 5Y11.89%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1817.18%
Revenue Next 2Y2556.94%
Revenue Next 3Y964.73%
Revenue Next 5Y473.92%
EBIT growth 1Y1.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year22.71%
EBIT Next 3Y10.88%
EBIT Next 5YN/A
FCF growth 1Y6.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.32%
OCF growth 3YN/A
OCF growth 5YN/A

ROCKET PHARMACEUTICALS INC / RCKT FAQ

What is the fundamental rating for RCKT stock?

ChartMill assigns a fundamental rating of 2 / 10 to RCKT.


What is the valuation status of ROCKET PHARMACEUTICALS INC (RCKT) stock?

ChartMill assigns a valuation rating of 0 / 10 to ROCKET PHARMACEUTICALS INC (RCKT). This can be considered as Overvalued.


How profitable is ROCKET PHARMACEUTICALS INC (RCKT) stock?

ROCKET PHARMACEUTICALS INC (RCKT) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ROCKET PHARMACEUTICALS INC?

The Earnings per Share (EPS) of ROCKET PHARMACEUTICALS INC (RCKT) is expected to grow by 20.79% in the next year.